Dyne Therapeutics is a biotechnology business based in the US. Dyne Therapeutics shares (DYN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $29.99 – a decrease of 1.06% over the previous week. Dyne Therapeutics employs 152 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $29.99 |
|---|---|
| 52-week range | $10.03 - $47.45 |
| 50-day moving average | $32.64 |
| 200-day moving average | $32.13 |
| Wall St. target price | $51.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.58 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $29.68 from 2024-11-19
| 1 week (2024-11-15) | 4.54% |
|---|---|
| 1 month (2024-10-21) | -11.35% |
| 3 months (2024-08-21) | -36.90% |
| 6 months (2024-05-21) | -9.04% |
| 1 year (2023-11-21) | 182.40% |
|---|---|
| 2 years (2022-11-21) | 216.76% |
| 3 years (2021-11-19) | 87.97% |
| 5 years (2019-11-18) | N/A |
Valuing Dyne Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Dyne Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Dyne Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.19. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Dyne Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Dyne Therapeutics's PEG ratio in relation to those of similar companies.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -40.35% |
| Return on equity TTM | -68.68% |
| Profit margin | 0% |
| Book value | $6.93 |
| Market Capitalization | $3.1 billion |
TTM: trailing 12 months
We're not expecting Dyne Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Dyne Therapeutics's shares have ranged in value from as little as $10.03 up to $47.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dyne Therapeutics's is 1.095. This would suggest that Dyne Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Dyne Therapeutics's beta into context you can compare it against those of similar companies.
Dyne Therapeutics, Inc. , a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.